Helicobacter pylori affects nearly half of the world's population and is a major pathogen associated with prevalent gastrointestinal disorders, including peptic ulcer and gastric cancer. Various diagnostic methods are available to detect infection, and the choice of method depends on factors such as their accessibility, advantages and disadvantages and cost. New treatment options for eradicating H. pylori have emerged as a result of the decreased efficacy of standard triple therapy due to increasing antibiotic resistance. This work reviews the main diagnostic methods used to identify H. pylori infection and to confirm the eradication of infection. We also provide a comprehensive overview of current and emerging strategies for the treatment of H. pylori infection. (Korean J Med 2015;89:149-156) 
Sequential therapy A 5-day dual therapy with a PPI (standard dose, bid) and amoxicillin (1 g, bid) followed by a 5-day triple therapy with a PPI (standard dose, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid)
Non-bismuth quadruple "concomitant therapy" A PPI (standard dose, bid), clarithromycin (500 mg, bid), amoxicillin (1 g, bid) and metronidazole (500 mg, bid) for 10-14 days
Hybrid therapy A 7-day dual therapy with a PPI (standard dose, bid) and amoxicillin (1 g, bid) followed by a 7-day quadruple therapy with a PPI (standard dose, bid), amoxicillin (1 g, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid)
Second-line/rescue therapies Levofloxacin-based triple therapy A PPI (standard dose, bid), levofloxacin (500 mg, bid) and amoxicillin (1 g, bid) for 10 days Rifabutin-based triple therapy A PPI (standard dose, bid), rifabutin (150 mg, bid) and amoxicillin (1 g, bid) for 10-14 days PPI, proton pump inhibitor. 중심 단어: 헬리코박터 파일로리; 진단; 치료
